Chemotherapies according to emetic potential
|
|
High emetogenicity
Group 1
|
Moderate emetogenicity
Group 2
|
Low/minimal emetogenicity
Group 3
|
| All cisplatin-containing regimens (CiFu, GemCis, BEP, TIP, VIP, PV, AP, EDP, DHAP, ECX, weekly dose cisplatin, and others) |
BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosfamide, vincristine, prokarbazine, prednisolone)
|
Doxorubicin/epirubicine weekly dose
|
| Doxorubicin/ifosfamide |
Bendamustine
|
Docetaxel |
FEC-60 og FEC-100
(fluorouracil, epirubicin, cyklophosfamide) |
Carboplatin
|
ENAP (etoposide, mitoxsantrone, cytarabine, prednisolone) |
| ABVD (doxorubicin, bleomycin, vinblastine, dakarbazine |
Carboplatin/pemetrexed
|
FLv (fluorouracil) |
FOLFIRINOX
|
Carboplatin/vinorelbine
|
FuMi (fluorouracil, mitomycin) |
|
CHOP (cyclophosfamide, doxorubicin, vincristine, prednisolone)
|
Gemcitabine |
|
CHOEP (cyclophosfamide, doxorubicin, vincristine, etoposide, prednisolone)
|
Methotrexate weekly dose |
| |
Dakarbazine
|
Navelbine |
| |
ECO/ACO (epirubicin/doxorubicin, cyclophosfamide, vincristine)
|
Paclitaxel |
| |
EOX (epirubicin, oxaliplatin, capecitabine)
|
Pemetrexed
|
| |
EPOCH-F (etoposide, prednisolone, vincristine, cyclofosfamide, doxorubicin, fludarabine)
|
|
| |
EPOCH-F (etoposide, prednisolone, vincristine, cyclophosfamide, doxorubicin, fludarabine)
|
|
| |
FLIRI (fluorouracil, irinotecan)
|
|
| |
FLOX (fluorouracil, oxaliplatin) |
|
| |
Gemcitabine/carboplatin |
|
| |
HD-Cytarabine
|
|
| |
HD-Methotrexate |
|
| |
IGEV (ifosfamide, gemcitabine, vinorelbine)
|
|
| |
IME (ifosfamide, methotreksate, etoposide) |
|
| |
Irinotecan |
|
| |
Streptozocin |
|
| |
Vorphase (cyclophosfamide)
|
|